Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost‐effective in select individuals
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15558 ↗Kurz gefasst
Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Darren Lau und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus, Type 2, Cost-Benefit Analysis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Medicine, University of Alberta, Department of Medicine, Georgetown University.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Many adults with diabetes are not on a statin.1 A coronary artery calcium (CAC) scan provides a depiction of coronary artery disease and is predictive of cardiovascular (CV) risk. Showing and discussing CAC scan findings with patients has been shown to increase the use of preventive medications.2, 3 Even in trials where CAC-based intervention reduced the use of statins (e.g., due to enrolment of healthier individuals at lower CV risk), the distribution of statin use shifted toward higher-risk individuals,4 with overall reductions in CV risk.2 CAC scans may be considered a form of personalized medicine, with incremental utility dependent on judicious patient selection.5, 6 Guidelines recommend the use of CAC scans in intermediate-risk individuals to help decide whether to start statin therapy. Since people aged ≥ 40 years with diabetes are uniformly considered statin-indicated, guidelines do not recommend CAC scans in adults with diabetes.7 However, CV risk can vary among adults with diabetes, and CAC scans may help to increase statin use.8 We performed an economic evaluation to explore the potential cost-effectiveness of CAC-guided risk counselling, compared to traditional risk factor counselling, among adults with diabetes who were not on statin therapy. We developed a Markov model of individuals with diabetes and no previous CV disease, who were not on statin therapy. Two age bands were chosen: men and women aged 60–69 years, consistent with the mean age of reported CAC cohorts,8 and men and women aged 40–49 years, the threshold for statin use in Canadian guidelines. The base cohort was men aged 60–69 years. Underlying CV risk without statin therapy was estimated from Alberta data. The distribution of CAC scores and the relative CV risk of each CAC score subgroup were derived from the published cohorts.8, 9 The intervention was CAC-guided counselling, while the control was traditional risk factor counselling. Their effects on statin use were obtained from the EISNER trial, which randomized individuals with CV risk factors to CAC-guided counselling or standard nurse practitioner counselling. Among those not on statin at baseline (n = 1482), the frequency of statin use after CAC-guided counselling was 22.9% overall, but ranged from 19% (CAC = 0) to 65% (CAC ≥ 400) depending on the revealed CAC score. We took this graded response to revealed CAC to be the effect of CAC-guided counselling. In contrast, the effect of traditional risk factor counselling was statin use in 25%, regardless of CV risk. Cost-effectiveness was evaluated from a Canadian healthcare payer perspective using probabilistic modelling (1000 re-samplings) over a 10-year horizon, with outcomes as shown (Figure 1). Statin use was assumed to reduce stroke and myocardial infarction risk. Health utility and costs (2020 Canadian dollars [CAD]) were estimated from literature and public sources. In Alberta, CAC scans are privately funded with a charge of $475 CAD.10 We considered CAC-guided risk counselling cost-effective if it improved outcomes at an incremental cost-effectiveness ratio (ICER) of 80% of re-samplings. One-way sensitivity analyses were performed, in addition to two scenario analyses: (1) we lowered the price of a CAC scan to $200 and (2) we simulated individuals who refuse statin therapy (control arm statin use = 0%), but would reconsider if shown a 'positive' CAC scan (intervention arm statin use 19%–65%, as above). Additional details are available in the supplementary material. Men aged 60–69 years provided with CAC-guided counselling would increase their overall statin use to 44% in a risk-dependent manner, compared to statin use of 25%, uniformly distributed across all risk categories among those provided with traditional risk factor counselling only. CAC-guided counselling was projected to lead to 8.4 fewer cases of acute coronary syndrome, 5.5 fewer strokes and 1.6 fewer deaths per 1000 individuals over 10 years. The number of additional scan-associated cancers was 8 per 100 000 individuals. The mean ICER was $6415/QALY (median $609/QALY; Table 1A), and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
ORCID-Profile: Darren Lau
Förderung
- Department of Medicine, University of Alberta
- Department of Medicine, Georgetown University
Zitieren
APA
Lau, D., Pearson, G. J., Raggi, P., & Klarenbach, S. (2024). Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost‐effective in select individuals. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15558
Vancouver
Lau D, Pearson GJ, Raggi P, Klarenbach S. Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost‐effective in select individuals. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15558
BibTeX
@article{Lau2024,
author = {Lau, Darren and Pearson, Glen J and Raggi, Paolo and Klarenbach, Scott},
title = {Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost‐effective in select individuals},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15558}
}
EUVIMED